GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Additional Paid-In Capital

Apontis Pharma AG (XTER:APPH) Additional Paid-In Capital : €34.61 Mil(As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG Additional Paid-In Capital?


Apontis Pharma AG's quarterly additional paid-in capital stayed the same from Dec. 2023 (€34.61 Mil) to Jun. 2024 (€34.61 Mil) and stayed the same from Jun. 2024 (€34.61 Mil) to Dec. 2024 (€34.61 Mil).

Apontis Pharma AG's annual additional paid-in capital stayed the same from Dec. 2022 (€34.61 Mil) to Dec. 2023 (€34.61 Mil) and stayed the same from Dec. 2023 (€34.61 Mil) to Dec. 2024 (€34.61 Mil).

Apontis Pharma AG Additional Paid-In Capital Historical Data

The historical data trend for Apontis Pharma AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG Additional Paid-In Capital Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial 6.75 36.28 34.61 34.61 34.61

Apontis Pharma AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.61 34.61 34.61 34.61 34.61

Apontis Pharma AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Apontis Pharma AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Apontis Pharma AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:B8FK ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904
Traded in Other Exchanges
N/A
Address
Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Website
https://www.apontis-pharma.de
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
Executives
Bruno Wohlschlegel Board of Directors
Thomas Milz Board of Directors
Thomas Zimmermann Chief Financial Officer
Karlheinz Gast Board of Directors

Apontis Pharma AG Headlines

No Headlines